Narayana Hrudayalaya Q4FY25 Earnings: The Numbers That Matter

Narayana Hrudayalaya (NARH) has just shared its Q4FY25 results, giving us a clear picture of how things went in the latest quarter. Let’s break down the important numbers and understand their significance.

Solid Earnings Beat Expectations

One of the standout points is that NARH’s EBITDA came in 6% higher than estimated. This means the company delivered better operational profitability than the market expected for the quarter, which is a positive sign.

Sales Growth Driven by Realisations

Sales in India grew by 7% year-on-year to about ₹1,100 crore. This growth was largely driven by better realisations — essentially, the company is generating more revenue per unit of service. This increase is notable, especially since the company did not add new capacity in terms of beds during the year.

Bed Reconfiguration Boosts Revenue Per Bed

Interestingly, rather than expanding capacity by adding beds, NARH focused on reconfiguring its existing beds. This strategy appears to be working well, as it led to a robust 13% year-on-year growth in average revenue per occupied bed (ARPOB) during the quarter. Simply put, they are making more revenue from the beds they already operate.

No New Beds Added in FY25, But Expansion Plans Are Underway

While FY25 saw no new beds added, NARH has plans to add about 2,000 beds, mainly across its core clusters. This planned expansion could support growth in the coming years and is an important factor for investors to watch.

Snapshot of Key Numbers

Market Valuation and Recommendation

The stock is currently trading at ₹1,742, just above the updated fair value of ₹1,705 (calculated by rolling forward to June 2027). After a sharp rally of about 40% in the past six months, the recommendation has shifted from ADD to REDUCE. This suggests a more cautious stance, given the recent run-up in the share price.

What This Means for Investors

Narayana Hrudayalaya’s Q4FY25 results show that the company is delivering stronger earnings and sales than expected. The focus on optimising existing capacity — improving revenue per occupied bed rather than adding new beds — is helping growth in the short term.

However, no new beds were added in FY25, which might limit near-term expansion. That said, the plan to add 2,000 beds going forward is a positive sign for future growth potential.

One caution is the company’s valuation, which remains under pressure due to lower domestic margins compared to peers. The sharp share price increase over recent months has led to a downgrade in recommendation, signalling investors should take a measured approach.

Summary Table: Performance and Outlook

Final Thoughts

To sum up, Narayana Hrudayalaya’s Q4FY25 performance underscores solid operational execution, with better-than-expected earnings and growth in sales and revenue per bed. The absence of new capacity additions in FY25 means growth has come mainly from making better use of existing assets.

Looking ahead, the planned bed additions could drive further growth, but investors should weigh this against valuation concerns and the recent strong run-up in the share price. The updated fair value and cautious recommendation reflect this balance.